Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

CDC Reports First Chikungunya Case Acquired in the U.S.

July 18, 2014 11:31 am | News | Comments

Seven months after the mosquito-borne virus chikungunya was recognized in the Western Hemisphere, the first locally acquired case of the disease has surfaced in the continental United States in Florida in a male who had not recently traveled outside the United States. Read more...

TOPICS:

Unrecognized Layer of Biology Promises New Drug Targets

July 18, 2014 11:24 am | News | Comments

Scientists at The Scripps Research Institute and Hong Kong University of Science and Technology and their collaborators have found that ancient enzymes, known for their fundamental role in translating genetic information into proteins, evolved myriad other functions in humans. Read more...

TOPICS:

AstraZeneca Reveals Plans for Cambridge Site

July 18, 2014 11:15 am | News | Comments

AstraZeneca revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters, including designs for the Global Centre, an R&D Enabling Building and an Energy Centre located on the Cambridge Biomedical Campus, Cambridge, UK. Read more...

TOPICS:
Advertisement

AbbVie, Shire Agree on Roughly $55B Combination

July 18, 2014 11:05 am | by Tom Murphy, The Associated Press | News | Comments

The drugmaker AbbVie has reached a deal worth roughly $55 billion to combine with British counterpart Shire and become the latest U.S. company to seek an overseas haven from corporate income tax rates back home when the new company is incorporated on the British island of Jersey. Read more...

TOPICS:

Researchers Create Biological Pacemakers with Gene Therapy

July 18, 2014 10:59 am | News | Comments

Cardiologists at the Cedars-Sinai Heart Institute have developed a minimally invasive gene transplant procedure that changes unspecialized heart cells into “biological pacemaker” cells that keep the heart steadily beating, potentially leading lead to clinical trials for humans with heart rhythm disorders but suffer side effects. Read more...

TOPICS:

NEJM Publishes Ipsen Data Showing Prolonged PFS from Somatuline

July 17, 2014 2:44 pm | News | Comments

Ipsen announced that the New England Journal of Medicine has published clinical trial results showing that Somatuline injection achieved statistically significant prolongation of progression free survival over placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors. Read more...

TOPICS:

Nintedanib Gets FDA Breakthrough Therapy Designation for IPF

July 17, 2014 2:16 pm | News | Comments

Boehringer Ingelheim Pharmaceuticals Inc. announced that the FDA has granted Breakthrough Therapy designation to nintedanib, an investigational therapy currently under review for the treatment of people with idiopathic pulmonary fibrosis (IPF). Read more...

TOPICS:

FDA Approves Salix-Pharming Angioedema Treatment

July 17, 2014 2:07 pm | News | Comments

Salix Pharmaceuticals Ltd. and Pharming Group NV announced that the FDA has approved Ruconest for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema (HAE). Read more...         

TOPICS:
Advertisement

BMS, Pfizer Launch Phase 4 Eliquis Trial

July 17, 2014 1:54 pm | News | Comments

Bristol-Myers Squibb and Pfizer announced that the first patient has been enrolled into a Phase 4 clinical trial called EMANATE, assessing the effectiveness and safety of Eliquis in patients with nonvalvular atrial fibrillation (NVAF) undergoing cardioversion. Read more...

TOPICS:

Arthritis Drug Shown to Slow Alzheimer’s

July 17, 2014 1:45 pm | News | Comments

A drug that is commonly used for arthritis has been shown to slow the progression of Alzheimer’s. A small randomized control study tested the drug Etanercept on patients with mild to moderate Alzheimer’s. Read more...          

TOPICS:

Protein Injection Halts Diabetes in Mice

July 17, 2014 1:36 pm | Videos | Comments

In mice with diet-induced diabetes—the equivalent of type 2 diabetes in humans—a single injection of the protein FGF1 is enough to restore blood sugar levels to a healthy range for more than two days. The discovery could lead to a new generation of diabetes drugs. Read more...

TOPICS:

Biotie Selects CDR System for Parkinson's Trial

July 17, 2014 11:11 am | News | Comments

Bracket is pleased to announce that Biotie Therapies, a specialized drug development company focusing on products for neurodegenerative and psychiatric disorders, has selected the CDR System for use as the primary endpoint for their Phase 2 trial of SYN120, an orally administered, dual 5HT6/5HT2a antagonist. Read more...

TOPICS:

Wales Kicks Off Hub to Accelerate Growth in Life Sciences

July 17, 2014 11:07 am | News | Comments

The Welsh Government has launched the Life Sciences Hub Wales, which will create a vibrant and prosperous Life Sciences ecosystem bringing together academic, business, clinical, professional services and funding organizations to provide a commercially-driven melting pot of talent. Read more...

TOPICS:

Medicines Patent Pool Speeds Availability of Generic HIV Drugs

July 17, 2014 11:00 am | News | Comments

Three days before the start of the 20th International AIDS Conference in Melbourne, Australia, the Medicines Patent Pool (MPP) announced seven new sub-licensing agreements for the manufacture of generic HIV medicines, atazanavir (ATV) and dolutegravir (DTG). Read more...

TOPICS:

Studies Reveal New Niacin Risks

July 17, 2014 10:54 am | by Marilynn Marchione, AP Chief Medical Writer | News | Comments

New details from two studies reveal more side effects from niacin, a drug that hundreds of thousands of Americans take for cholesterol problems and general heart health. Some prominent doctors say the drug now seems too risky for routine use. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading